Key points are not available for this paper at this time.
A study that assessed the risk of diabetic ketoacidosis after the initiation of SGLT2 inhibitor therapy showed nearly twice the risk as with a DPP4 inhibitor.
Fralick et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: